Zenas BioPharma

Zenas BioPharma (Nasdaq: ZBIO) is a clinical-stage global biopharmaceutical company committed to becoming a leader in the development and commercialization of transformative immunology-based therapies for patients in need. Our core business strategy combines our experienced leadership team with a disciplined product candidate acquisition approach to identify, acquire and develop product candidates globally that we believe can provide superior clinical benefits to patients living with autoimmune diseases. Zenas lead product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcRIIb, which are broadly present across B cell lineage, to inhibit the activity of cells that are implicated...

Autoimmune diseases and immunology

Zenas biopharma operates in the Biotechnology research industry.

Zenas biopharma's revenue is 11m - 100m

Zenas biopharma has 51 - 200 employees.